Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus

Eriko Sato, Ikuko Yano, Masahiro Shimomuro, Satohiro Masuda, Toshiya Katsura, Shin Ichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Shinji Uemoto, Ken Ichi Inui

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. Both patients were administered tacrolimus with sirolimus or everolimus. They had been administered 5 or 9 mg sirolimus once a day and had maintained a trough concentration of about 15 ng/mL as measured by high performance liquid chromatography with ultraviolet detection. After the switch from sirolimus to everolimus, they were given 10 or 12 mg/day of everolimus twice a day to maintain a trough concentration of 12-15 ng/mL as measured by a fluorescence polarization immunoassay (FPIA) method. Afterward, the blood concentrations of everolimus and sirolimus after the conversion were measured by high performance liquid chromatography with mass spectrometry and everolimus concentrations were found to be 5-10 ng/mL. These data show that a larger dosage is needed for everolimus than sirolimus to maintain the same trough blood concentration. Data obtained by the FPIA for everolimus should be carefully evaluated after switching from sirolimus to everolimus because of the cross-reactivity of the antibody with sirolimus.

Original languageEnglish
Pages (from-to)175-179
Number of pages5
JournalDrug metabolism and pharmacokinetics
Volume24
Issue number2
DOIs
Publication statusPublished - Jan 1 2009
Externally publishedYes

Fingerprint

Tacrolimus
Sirolimus
Islets of Langerhans
Transplants
Fluorescence Polarization Immunoassay
High Pressure Liquid Chromatography
Everolimus
Mass Spectrometry
Japan
Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. / Sato, Eriko; Yano, Ikuko; Shimomuro, Masahiro; Masuda, Satohiro; Katsura, Toshiya; Matsumoto, Shin Ichi; Okitsu, Teru; Iwanaga, Yasuhiro; Uemoto, Shinji; Inui, Ken Ichi.

In: Drug metabolism and pharmacokinetics, Vol. 24, No. 2, 01.01.2009, p. 175-179.

Research output: Contribution to journalArticle

Sato, Eriko ; Yano, Ikuko ; Shimomuro, Masahiro ; Masuda, Satohiro ; Katsura, Toshiya ; Matsumoto, Shin Ichi ; Okitsu, Teru ; Iwanaga, Yasuhiro ; Uemoto, Shinji ; Inui, Ken Ichi. / Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus. In: Drug metabolism and pharmacokinetics. 2009 ; Vol. 24, No. 2. pp. 175-179.
@article{9728db67c3434136a8ad5eebf99c043f,
title = "Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus",
abstract = "We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. Both patients were administered tacrolimus with sirolimus or everolimus. They had been administered 5 or 9 mg sirolimus once a day and had maintained a trough concentration of about 15 ng/mL as measured by high performance liquid chromatography with ultraviolet detection. After the switch from sirolimus to everolimus, they were given 10 or 12 mg/day of everolimus twice a day to maintain a trough concentration of 12-15 ng/mL as measured by a fluorescence polarization immunoassay (FPIA) method. Afterward, the blood concentrations of everolimus and sirolimus after the conversion were measured by high performance liquid chromatography with mass spectrometry and everolimus concentrations were found to be 5-10 ng/mL. These data show that a larger dosage is needed for everolimus than sirolimus to maintain the same trough blood concentration. Data obtained by the FPIA for everolimus should be carefully evaluated after switching from sirolimus to everolimus because of the cross-reactivity of the antibody with sirolimus.",
author = "Eriko Sato and Ikuko Yano and Masahiro Shimomuro and Satohiro Masuda and Toshiya Katsura and Matsumoto, {Shin Ichi} and Teru Okitsu and Yasuhiro Iwanaga and Shinji Uemoto and Inui, {Ken Ichi}",
year = "2009",
month = "1",
day = "1",
doi = "10.2133/dmpk.24.175",
language = "English",
volume = "24",
pages = "175--179",
journal = "Drug Metabolism and Pharmacokinetics",
issn = "1347-4367",
publisher = "Japanese Society for the Study of Xenobiotics",
number = "2",

}

TY - JOUR

T1 - Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus

AU - Sato, Eriko

AU - Yano, Ikuko

AU - Shimomuro, Masahiro

AU - Masuda, Satohiro

AU - Katsura, Toshiya

AU - Matsumoto, Shin Ichi

AU - Okitsu, Teru

AU - Iwanaga, Yasuhiro

AU - Uemoto, Shinji

AU - Inui, Ken Ichi

PY - 2009/1/1

Y1 - 2009/1/1

N2 - We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. Both patients were administered tacrolimus with sirolimus or everolimus. They had been administered 5 or 9 mg sirolimus once a day and had maintained a trough concentration of about 15 ng/mL as measured by high performance liquid chromatography with ultraviolet detection. After the switch from sirolimus to everolimus, they were given 10 or 12 mg/day of everolimus twice a day to maintain a trough concentration of 12-15 ng/mL as measured by a fluorescence polarization immunoassay (FPIA) method. Afterward, the blood concentrations of everolimus and sirolimus after the conversion were measured by high performance liquid chromatography with mass spectrometry and everolimus concentrations were found to be 5-10 ng/mL. These data show that a larger dosage is needed for everolimus than sirolimus to maintain the same trough blood concentration. Data obtained by the FPIA for everolimus should be carefully evaluated after switching from sirolimus to everolimus because of the cross-reactivity of the antibody with sirolimus.

AB - We attempted a switch of mammalian target of rapamycin (mTOR) inhibitors from sirolimus to everolimus, a derivative of sirolimus and now on the market in Japan, in two pancreatic islet transplant patients. Both patients were administered tacrolimus with sirolimus or everolimus. They had been administered 5 or 9 mg sirolimus once a day and had maintained a trough concentration of about 15 ng/mL as measured by high performance liquid chromatography with ultraviolet detection. After the switch from sirolimus to everolimus, they were given 10 or 12 mg/day of everolimus twice a day to maintain a trough concentration of 12-15 ng/mL as measured by a fluorescence polarization immunoassay (FPIA) method. Afterward, the blood concentrations of everolimus and sirolimus after the conversion were measured by high performance liquid chromatography with mass spectrometry and everolimus concentrations were found to be 5-10 ng/mL. These data show that a larger dosage is needed for everolimus than sirolimus to maintain the same trough blood concentration. Data obtained by the FPIA for everolimus should be carefully evaluated after switching from sirolimus to everolimus because of the cross-reactivity of the antibody with sirolimus.

UR - http://www.scopus.com/inward/record.url?scp=67649342624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649342624&partnerID=8YFLogxK

U2 - 10.2133/dmpk.24.175

DO - 10.2133/dmpk.24.175

M3 - Article

C2 - 19430174

AN - SCOPUS:67649342624

VL - 24

SP - 175

EP - 179

JO - Drug Metabolism and Pharmacokinetics

JF - Drug Metabolism and Pharmacokinetics

SN - 1347-4367

IS - 2

ER -